[CAS NO. 6190-39-2] Dihydroergotamine mesylate
PRODUCTS SPECIFICATIONS [6190-39-2]
DESCRIPTION [6190-39-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 679.78 |
| Molecular Formula | C34H41N5O8S |
| SMILES | O[C@@]([C@@](CCC1)([H])N1C2=O)(O[C@](NC([C@@H](CN(C)[C@]3([H])C4)C[C@]3([H])C5=C6C4=CNC6=CC=C5)=O)(C)C7=O)N7[C@H]2CC8=CC=CC=C8.CS(=O)(O)=O |
1 Publications Citing Use of MCE
Summary
Dihydroergotamine mesylate is an ergot alkaloid used to treat migraines. Target: 5-HT Receptors Dihydroergotamine is not as effective as sumatriptan or phenothiazines as a single agent for treatment of acute migraine headache; however, when administered with an antiemetic, dihydroergotamine appears to be as effective as opiates, ketorolac, or valproate. Given its nonnarcotic properties, parenteral dihydroergotamine combined with an antiemetic should be considered as effective initial therapy in clinical practice [1]. The introduction of the intranasal formulation of DHE provides both pharmacologic and patient-convenience advantages for use in migraine therapy [2, 3].
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01089062 | Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan |
Healthy
|
March 2010 | Phase 1 |
| NCT03401346 | Impel Pharmaceuticals |
Migraine Headache
|
October 19, 2017 | Phase 1 |
| NCT03874832 | Satsuma Pharmaceuticals, Inc. |
Migraine With Aura|Migraine Without Aura|Migraine
|
September 11, 2018 | Phase 1 |
| NCT05351086 | Pulmatrix Inc. |
Healthy
|
June 9, 2022 | Phase 1 |
| NCT00203268 | Thomas Jefferson University|Bausch Health Americas, Inc. |
Migraine
|
December 2003 | Not Applicable |
| NCT04940390 | Satsuma Pharmaceuticals, Inc. |
Migraine|Migraine With Aura|Migraine Without Aura
|
June 30, 2021 | Phase 3 |
| NCT04406649 | Satsuma Pharmaceuticals, Inc. |
Migraine|Migraine With Aura|Migraine Without Aura
|
September 14, 2020 | Phase 3 |
| NCT03885154 | Kimberly S Jones|University of Kentucky |
Migraine in Children
|
October 3, 2017 | Phase 2 |
| NCT03901482 | Satsuma Pharmaceuticals, Inc. |
Migraine|Migraine With Aura|Migraine Without Aura
|
June 24, 2019 | Phase 3 |
| NCT05337254 | Satsuma Pharmaceuticals, Inc. |
Migraine|Migraine With Aura|Migraine Without Aura
|
March 5, 2021 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 50 mg/mL ( 73.55 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.4711 mL | 7.3553 mL | 14.7106 mL |
| 5 mM | 0.2942 mL | 1.4711 mL | 2.9421 mL |
| 10 mM | 0.1471 mL | 0.7355 mL | 1.4711 mL |
References
- [1] Colman, I., et al., Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med, 2005. 45(4): p. 393-401.
- [2] Saper, J.R., et al., DHE in the pharmacotherapy of migraine: potential for a larger role. Headache, 2006. 46 Suppl 4: p. S212-20.
- [3] Schaerlinger, B., et al., Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol, 2003. 140(2): p. 277-84.
Synonyms